Ritholtz Wealth Management Purchases 33,249 Shares of Haleon plc (NYSE:HLN)

Ritholtz Wealth Management lifted its position in Haleon plc (NYSE:HLN - Free Report) by 128.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 59,214 shares of the company's stock after buying an additional 33,249 shares during the period. Ritholtz Wealth Management's holdings in Haleon were worth $565,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the company. Fortitude Family Office LLC purchased a new stake in shares of Haleon in the 3rd quarter worth $28,000. Versant Capital Management Inc increased its position in Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock worth $34,000 after buying an additional 3,348 shares in the last quarter. Toronto Dominion Bank raised its stake in shares of Haleon by 3,470.0% in the third quarter. Toronto Dominion Bank now owns 3,570 shares of the company's stock worth $38,000 after buying an additional 3,470 shares during the period. Prospera Private Wealth LLC purchased a new position in shares of Haleon during the 3rd quarter valued at about $57,000. Finally, Hexagon Capital Partners LLC lifted its position in shares of Haleon by 18.5% during the 3rd quarter. Hexagon Capital Partners LLC now owns 7,933 shares of the company's stock valued at $84,000 after buying an additional 1,238 shares in the last quarter. Institutional investors own 6.67% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Morgan Stanley cut shares of Haleon from an "overweight" rating to an "equal weight" rating in a research note on Friday, January 10th. Sanford C. Bernstein cut shares of Haleon from an "outperform" rating to a "market perform" rating in a research note on Wednesday, January 8th. Finally, UBS Group upgraded Haleon to a "strong-buy" rating in a research note on Tuesday, October 1st. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $10.95.

Haleon Price Performance

Shares of Haleon stock traded down $0.02 on Tuesday, hitting $9.23. 8,342,520 shares of the company traded hands, compared to its average volume of 12,141,513. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80. The business has a 50-day simple moving average of $9.54 and a 200 day simple moving average of $9.72. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a market capitalization of $41.76 billion, a P/E ratio of 27.13, a price-to-earnings-growth ratio of 2.59 and a beta of 0.29.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.